If you are taking a statin, managing heart failure, or simply watching your energy fade as you age, CoQ10 (coenzyme Q10) is one of the few blood markers that can show you whether your cells have enough fuel to keep up. Your body makes this molecule on its own, but production drops with age, and certain medications can slash it further. A low reading does not mean you have a disease today, but it does mean your cells are running on a thinner energy margin, and that margin matters more than most people realize.
CoQ10 sits at the crossroads of energy production and damage control. It is the molecule your cells depend on to generate the chemical energy currency called ATP (adenosine triphosphate), and it doubles as one of the body's most important fat-soluble antioxidants. When levels drop, the effects ripple outward: your heart muscle works less efficiently, your blood vessels lose some of their protective cushion, and oxidative damage accumulates faster than your repair systems can handle.
CoQ10 is a fat-soluble compound that lives primarily inside mitochondria, the tiny energy-producing compartments in your cells. Its day job is shuttling electrons along the chain of reactions that converts the food you eat into usable cellular energy. Without enough CoQ10, that chain stutters, and your highest-demand organs, particularly the heart, liver, and kidneys, feel the slowdown first.
It exists in two forms: an oxidized form called ubiquinone and a reduced form called ubiquinol. The reduced form is the one that acts as an antioxidant, neutralizing reactive oxygen molecules before they can damage cell membranes and the cholesterol particles circulating in your blood. In healthy people, about 90% or more of the CoQ10 in blood is in the reduced, protective form.
Your body makes CoQ10 through a pathway it shares with cholesterol production, called the mevalonate pathway. This is why statins, which block a key enzyme in that pathway (HMG-CoA reductase, the same enzyme targeted to lower cholesterol), also reduce your body's CoQ10 output as a side effect.
The strongest clinical evidence for CoQ10 as a biomarker and treatment target comes from heart failure. People with heart failure consistently show lower CoQ10 levels in both blood and heart tissue, and the degree of depletion tracks with symptom severity.
The Q-SYMBIO trial, a randomized, double-blind study of 420 people with chronic heart failure, is the landmark result. Participants who took 100 mg of CoQ10 three times daily for two years cut their risk of a major cardiovascular event roughly in half compared to placebo (15% versus 26% experienced events). Death from cardiovascular causes dropped from 16% to 9%, and overall death from any cause dropped from 18% to 10%. Symptom severity, measured by the standard heart failure grading system (NYHA class), also improved.
A systematic review pooling 26 randomized trials and 2,250 heart failure patients found that adding CoQ10 to standard therapy reduced the risk of heart failure hospitalization by about 39%. The effect on overall mortality trended in the right direction but did not reach statistical certainty across the full pool of smaller trials.
A 2025 randomized trial of 120 heart failure patients confirmed that CoQ10 supplementation improved cardiac function, reduced markers of cardiac stress, and enhanced both exercise capacity and quality of life. If you have heart failure or are at high risk for it, knowing your CoQ10 level gives you a starting point for a conversation about supplementation that is backed by real outcome data.
A dose-response meta-analysis of 40 randomized trials involving 2,424 participants found that CoQ10 supplementation lowered fasting blood sugar by about 5.2 mg/dL, fasting insulin by about 1.3 µIU/mL, and the insulin resistance score (HOMA-IR, a calculation combining fasting glucose and insulin to estimate how well your body responds to insulin) by 0.69 units. The optimal dose for blood sugar benefits appeared to be 100 to 200 mg per day, following a U-shaped curve where going higher did not add benefit.
In a separate trial of 101 adults with high cholesterol, 120 mg of CoQ10 daily for 24 weeks improved triglycerides, LDL cholesterol (low-density lipoprotein, the "bad" cholesterol), a protein called ApoA-I that helps with cholesterol clearance, and blood pressure. These metabolic improvements suggest CoQ10 status matters for anyone tracking insulin resistance or cardiovascular risk factors.
A meta-analysis of nine trials involving 428 participants found that CoQ10 supplementation raised circulating CoQ10 by about 1.17 µg/mL on average and reduced TNF-alpha (tumor necrosis factor alpha, a protein that drives inflammation) by 0.45 pg/mL. A larger updated meta-analysis of 31 trials and 1,517 participants confirmed that CoQ10 reduced all three major inflammatory markers: CRP (C-reactive protein), IL-6 (interleukin-6), and TNF-alpha, with doses of 300 to 400 mg per day showing the strongest anti-inflammatory effect.
Statins lower blood CoQ10 by blocking the shared production pathway. In a study of 67 patients after a heart attack who were newly started on a statin, plasma CoQ10 dropped by roughly 40%. This reduction goes beyond what you would expect from simply lowering cholesterol-carrying particles (which transport CoQ10 in the blood).
Whether this drop contributes to the muscle pain that some statin users experience remains debated. A meta-analysis of 12 randomized trials and 575 patients with statin-related muscle symptoms found that CoQ10 supplementation improved pain, weakness, cramping, and fatigue scores compared to placebo. However, it did not change creatine kinase (CK, an enzyme released when muscle cells are damaged), suggesting the benefit is through improved mitochondrial function rather than preventing actual muscle breakdown. A separate, well-controlled trial of 120 patients with confirmed statin muscle pain found no benefit from CoQ10 over placebo for pain specifically, so the evidence here is genuinely mixed.
A randomized trial of 45 migraine patients found that 400 mg of CoQ10 daily reduced the frequency, severity, and duration of migraine attacks compared to placebo, along with a reduction in TNF-alpha levels. The trial was small, but the result aligns with the broader theory that mitochondrial energy deficits play a role in migraine, and CoQ10 helps fill that gap.
No major clinical guidelines have established standardized reference ranges for plasma or serum CoQ10. The values below come from population studies using HPLC (high-performance liquid chromatography, the most common lab method for this test) and should be treated as orientation, not fixed targets. Your results may differ depending on your lab's specific assay.
Because CoQ10 travels in the blood attached to cholesterol-carrying particles, your total cholesterol level strongly influences your CoQ10 reading. A study of 860 European adults found that the correlation between CoQ10 and cholesterol was among the tightest of any biomarker pairing measured. Many experts recommend looking at your CoQ10 relative to your total cholesterol (the CoQ10-to-cholesterol ratio) for a more accurate picture. Women tend to have lower cholesterol-adjusted CoQ10 than men, and Black individuals tend to have higher absolute values than white individuals.
| Tier | Approximate Range | What It Suggests |
|---|---|---|
| Low | Below 0.5 µg/mL | Possible depletion, especially if on a statin or with chronic disease. Worth investigating further. |
| Typical | 0.5 to 1.5 µg/mL | Within the range seen in most healthy adults. Interpret relative to your cholesterol and medications. |
| Optimal / Supplemented | Above 1.5 µg/mL | Often seen with supplementation. In heart failure trials, a blood level around 3.5 to 4.1 µg/mL was associated with therapeutic benefit. |
| High (supplementation) | Above 4.0 µg/mL | Achievable with high-dose supplementation (600+ mg/day). No toxicity signal at these levels in clinical trials. |
These ranges are drawn from studies of 99 to 860 healthy European and American adults. Your lab may report results in different units (µmol/L instead of µg/mL; to convert, divide µg/mL by 0.863). Always compare your results within the same lab over time for the most meaningful trend.
The biggest confounder for CoQ10 testing is your cholesterol level. Because about 58% of plasma CoQ10 rides on LDL particles, anything that lowers your LDL will also pull your CoQ10 reading down, even if your cells have adequate CoQ10. This means statin users will almost always show lower numbers, and a portion of that drop is a measurement artifact rather than a true energy deficit.
Most research draws blood in the morning after an overnight fast for standardization, but the exact effect of meals or time of day on CoQ10 results has not been well quantified. Fasting for your draw is a reasonable precaution.
A single CoQ10 reading tells you where you stand today, but the real power of this test comes from tracking your number over time. CoQ10 levels have meaningful biological variability from one person to the next, and your own baseline matters more than any population average. A study of 10 healthy young men measured CoQ10 repeatedly and found that both the between-person and within-person variation are substantial enough that a single reading should not drive major decisions.
If you are starting a statin, get a baseline CoQ10 level before or shortly after initiation, then recheck in 3 to 6 months to see how much your production has dropped. If you start supplementing, recheck at 8 to 12 weeks to confirm your level is actually rising (absorption varies widely between individuals and between formulations). After that, annual monitoring is reasonable for anyone actively managing their level.
Watching the trend also lets you gauge whether an intervention is working. If you switch from ubiquinone to ubiquinol, or increase your dose, a follow-up draw three months later tells you whether the change actually moved your number. Without that data point, you are guessing.
If your CoQ10 is low (below 0.5 µg/mL), the first step is context. Are you on a statin or bisphosphonate? If so, the drug is likely pulling the number down. Supplementation with 100 to 300 mg of CoQ10 daily is well supported by trial data and is safe. Choose a formulation taken with a fat-containing meal for best absorption.
If your CoQ10 is low and you are NOT on a medication that explains it, consider checking your lipid panel, liver function (since the liver is the primary production site), and kidney function alongside it. Very low levels in a young person without obvious explanation may warrant genetic evaluation for primary CoQ10 biosynthesis defects, especially if there is unexplained kidney disease or neurological symptoms. An endocrinologist or metabolic specialist can guide that workup.
If you have heart failure or are at high risk, discuss CoQ10 supplementation at 300 mg daily with your cardiologist. The Q-SYMBIO data are compelling enough to justify this conversation, and the safety profile across decades of study is reassuring, with the most common side effects being mild digestive discomfort that improves with split dosing and taking with food.
Evidence-backed interventions that affect your CoQ10 level
CoQ10 is best interpreted alongside these tests.